Effects of different doses of acitretin on FGF10 mRNA transcription and its protein translation in HaCaT cells

Objective： To observe the effects of different doses of acitretin on the transcription of FGF10 mRNA and the translation of FGF10 protein in cultured HaCaT cells. Methods： HaCaT cells were treated with different doses of acitretin for 48 h, then the changes on the transcription of FGF10 mRNA and the translation of FGF10 protein in these cells were detected by immunofluorescence and in situ hybridization assay. Results： Compared with the control group, the transcription of FGF10 mRNA and the translation of FGF10 protein were gradually decreased along with the increasing dose of aeitretin. There were significant differences between different groups （P〈0.01）. Conclusion： Aeitretin could inhibit the transcription of FGF10 mRNA and the translation of FGF10 protein in HaCaT cells. With the dose of aeitretin increased, the stains of both FGF10 mRNA and FGF10 protein in HaCaT cells are reduced.

Comparison between synthetic retinoid CD437 and acitretin inhibiting melanoma A375 cell in vitro

Objective： To investigate the effects of synthetic retinoid CD437 and acitretin on cell proliferation, apoptosis, cycle arrest and Bax/ Bcl-2 protein expression of melanoma A375 cell, Methods：MTT assay was used to determine the anti-proliferative effects of CD437 and acitretin on melanoma A375 cell, Flow cytometry was performed to investigate the influence of CD437 and acitretin on cell cycle and cell apoptosis. SABC immunocytochemistry was employed for detection of Bax/bcl-2 protein expressions. Results：10^-5 mol/L CD437 was more effective than acitretin in inhibiting proliferation and inducing apoptosis of A375 cell after 24 h treatment, growth inhibiting ratio and apoptosis ratio（58.6%vs43.25% and 28.03%vs17.13%, P 〈 0.05 respectively）. CD437 promoted G0/G1 arrest in melanoma A375 cell, however acitretin could not. CD437 and acitretin could up-regulate the expression of Bax protein and downregulate the expression of bcl-2 protein（P 〈 0.05）. Conclusion：CD437 is more effective than acitretin in inhibiting proliferation and inducing apoptosis and cycle arrest on A375 cell, CD437 may have more potentialities than acitretin for subsidiary treatment of melanoma. Mitochondrial apoptosis pathway is partially involved in two drugs inducing apoptosis on A375 cell.

A Unique Case? Darier’s Disease Presented as Porcupine-Like Appearance and the Observation on Acitretin Treatment

Dyskeratosis follicularis (Darier’s disease, DD) is rare autosomal dominant disease characterized by hyperkeratotic papules that coalesce into plaques and occur primarily in seborrheic or intertriginous areas. Associated findings include nail abnormalities. A 3-year-old boy presented with porcupine-like appearance for 2 years. The lesion from the back was taken for light microscopy and electron microscopy. He was treated with acitretin (0.31 mg/d to 0.66 mg/d) for 8 years. Light microscopy and electron microscopy showed that the typical features of DD. The patient show good respond to the treatment. During 8 years treatment, the patient had dry mouth and pruritus. The skeletal abnormalities didn’t happen in the patient. The serum lipid profile, liver function and renal function within normal lever after treatment. Our findings showed that porcupine-like appearance is a unique pattern of DD. Acitretin may be a useful therapeutic agent in children with DD and less likely to cause skeletal problems.

Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris：A Randomized Clinical Trial

Background：Few clinical trials have evaluated the efficacy and safety of Tripterygium wilfordii Hook F （TwHF） compared with acitretin in psoriasis.We aimed to compare the efficacy and safety of TwHF compared with acitretin in the treatment of moderate to severe psoriasis vulgaris.Methods：Adults with Psoriasis Area Severity Index （PASI） score ＞ 10 and psoriasis-affected body surface area ＞ 10％ were randomized into a TwHF （20 mg,3 times a day） or acitretin group （30 mg,once a day）.The treatment course lasted for 8 weeks.Patients were assessed at baseline and at 2,4,and 8 weeks.Laboratory tests were performed at baseline,week 4,and week 8.The data were analyzed using paired samples t-test or analysis of variance （ANOVA）.Results：A total of 115 patients was enrolled （58 TwHF; 57 acitretin）.The median PASI score improved in the TwHF group by 50.4％ and in the acitretin group by 42.7％.There was no significant difference in median PASI improvement between two groups at 2,4,and 8 weeks.There was also no significant difference in PASI 25,PASI 50,PASI 75,and PASI 90 response between the two groups at 2,4,and 8 weeks.There was a significant increase in the level of aspartate transaminase and triglycerides in the TwHF group （P =0.026 and P =0.011,respectively）.In the acitretin group,there was a significant increase in the level of alanine transaminase,cholesterol,and high-density lipoprotein （P =0.030,P ＜ 0.01,and P ＜ 0.01,respectively）.Conclusions：There was no significant difference in treatment efficacy between the TwHF and acitretin groups within 8 weeks,but there were fewer treatment-related adverse events in the TwHF group.

Effect of Chinese Herbal Medicine Combined with Acitretin Capsule in Treating Psoriasis of Blood-Heat Syndrome Type

Objective:To observe the clinical curative effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome(P-BH).Methods:Eighty patients of P-BH were randomly assigned to two groups,39 in Group A and 41 in Group B.Both was treated with Chinese herbal medicines for clearing heat,cooling blood and removing toxic substance,and acitretin capsule was given to Group A additionally,with 8 weeks as one therapeutic course.The clinical curative effect was compared betwee...

A harlequin ichthyosis pig model with a novel ABCA12 mutation can be rescued by acitretin treatment

Harlequin ichthyosis (HI) is a severe genetic skin disorder and caused by mutation in the ATP-binding cassette A12 (ABCA12) gene. The retinoid administration has dramatically improved long-term survival of HI, but improvements are still needed. However, the ABCA12 null mice failed to respond to retinoid treatment, which impedes the development of novel cure strategies for HI. Here we generated an ethylnitrosourea mutagenic HI pig model (named Z9), which carries a novel deep intronic mutation IVS49-727 A>G in the ABCA12 gene, resulting in abnormal mRNA splicing and truncated protein production. Z9 pigs exhibit significant clinical symptom as human patients with HI. Most importantly, systemic retinoid treatment significantly prolonged the life span of the mutant pigs via improving epidermal maturation, decreasing epidermal apoptosis, and triggering the expression of ABCA6. Taken together, this pig model perfectly resembles the clinical symptom and molecular pathology of patients with HI and will be useful for understanding mechanistic insight and developing therapeutic strategies.

Assessment by HPLC of the degradation behavior of acitretin under hydrolytic,oxidative,photolytic and thermal stress conditions

Acitretin is a photosensitive oral retinoid with very limited data available on its degradation.The official HPLC method for acitretin determination was insufficient to resolve the degradation products generated during stability studies.Therefore,an isocratic RP-HPLC-UV method was developed for the determination of acitretin in the presence of its related impurities and degradation products.Efficient chromatographic separation was achieved on a Thermo beta-basic column C18(100 mm
4.6 mm,5μm)with mobile phase containing 0.3%(v/v)glacial acetic acid with acetonitrile(ACN)and isopropyl alcohol(IPA)in an isocratic ratio of 70:30 at a flow rate of 1.0 mL/min with the eluent monitored at 360 nm.The method was validated for specificity,linearity,precision,accuracy and robustness.The calibration plot was linear over the concentration range of 50-150μg/mL with a correlation coefficient(r2)of 0.999.The proposed method was used to investigate the degradation kinetics of acitretin under the different degradative conditions.The degradation rate constant(K),half-life(t1/2),and t90 were calculated.Degradation of acitretin followed pseudo-first-order kinetics.The drug was found to be less stable under acidic and photolytic degradation conditions:the photolytic degradation constants for acitretin in sunlight and UV light were 0.002698%and 0.0008402%min1,respectively.The LOD for acitretin and the known impurities were at a level below 0.02%.The method shows consistent recoveries for ACTR(99.8%-101.2%)and also for its known impurities(97.2-101.3%).The method was found to be accurate,precise,linear,specific,sensitive,rugged,robust,and useful for characterizing the stability of this chemical.

Impact of Adverse Events Associated With Acitretin Treatment of Moderate-to-Severe Plaque Psoriasis:Based on an Observational,Single-Center Study in Shanghai,China

Objective:Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events(AEs)among individuals.This study aimed to determine the impact of AEs associated with acitretin treatment of moderate-to-severe plaque psoriasis on the Dermatology Life Quality Index(DLQI)and Hospital Anxiety and Depression Scale(HADS)scores.Methods:This prospective,observational,single-center study was conducted from March 2021 to June 2022 and analyzed 116 patients with moderate-to-severe plaque psoriasis treated with acitretin who were followed up for 12 weeks.The primary outcome was the incidence of AEs related to acitretin,and the secondary objective was to investigate the effect of AEs on the DLQI and HADS scores.The generalized linear models were used to assess the association between AEs related to acitretin and DLQI scores or HADS scores,and the association between the involved system/tissue and DLQI scores or HADS scores.Results:A final total of 45 patients were included in the analysis,and a total of 157 treatment-related AEs involving nine organs or systems were reported in 41 patients.The most common AE was skin-or mucosa-related,with 72 cumulative events in 31 patients.AEs also commonly affected the endocrine,digestive,and genitourinary systems.Compared with the group with 0-2 AEs,the group with 3-5 AEs had a significantly increased DLQI score by 5.49 points(95%CI,1.47-9.51)(P=0.0089).Compared with AEs involving 0 to 1 system,AEs affecting 2 to 3 systems resulted in a significant increase in the DLQI score by 5.75 points(95%CI,1.67-9.83)(P=0.0071).Generalized linear models showed no statistically significant associations between AEs and the HADS scores.Conclusion:Our study demonstrates a high incidence of acitretin-related AEs.These AEs may affect quality of life but rarely cause psychological problems such as anxiety and depression.

Efficacy of Acitretin Monotherapy on Basal Cell Carcinoma:A Case Report

Introduction:Basal cell carcinoma(BCC)is the most common skin cancer which mainly affects the population over 50 years of age.In addition to surgical treatment,nonsurgical treatment is also an attractive option for some patients.We herein report a case of an 82-year-old man with BCC successfully treated with acitretin.Case presentation:An 82-year-old man presented with BCC on his left nose wing more than 2 years ago.Due to his unwillingness to accept treatment that may lead to pain,discomfort,or trauma,the patient was prescribed oral acitretin 25 mg twice daily[0.8 mg/(kg·d)]and was instructed to apply 2%fusidic acid cream topically once daily for trauma protection.The lesion progressively shrank in size after 4 weeks of treatment,and was almost completely resolved after 28 weeks of follow-up.The patient reported mild adverse effects,such as mild skin fragility and cheilitis,and apparent scaling skin,which caused minor discomfort but did not affect the continuation of treatment.Discussion:The pathogenesis of BCC is still unclear,but it has been demonstrated to be linked to overactive hedgehog signaling and its crosstalk with other pathways such as phosphoinositide 3-kinase and mammalian target of rapamycin.Acitretin could obviously inhibit cell growth and proliferation and down-regulate AMP-dependent protein kinases that plays critical role in the blocking of malignant progression of several tumors including BCC.Conclusion:We provide an effective alternative for the patients with BCC who are unwilling to receive surgical therapy.

窄谱中波紫外线联合阿维A对寻常型银屑病患者的炎症因子、免疫功能的影响探讨

目的探讨窄谱中波紫外线联合阿维A对寻常型银屑病的炎症因子、免疫功能的影响。方法70例符合入选标准的寻常型银屑病患者,按随机数字表法分为对照组(35例)和观察组(35例)。对照组给予窄谱中波紫外线照射治疗,观察组在对照组基础上口服阿维A治疗。比较两组临床疗效、不良反应发生情况及治疗前后T淋巴细胞亚群(CD^3(+)、CD^4(+)、CD^8(+))、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平。结果观察组临床总有效率94.29%(33/35)明显高于对照组74.29%(26/35)(P<0.05)。与观察组治疗前CD^4(+)(30.06±4.21)%及对照组治疗后CD^4(+)(34.38±3.47)%比较,观察组治疗后CD^4(+)(39.39±3.60)%显著升高(P<0.05);与观察组治疗前CD^8(+)(29.53±2.88)%及对照组治疗后CD^8(+)(26.50±2.48)%比较,观察组治疗后CD^8(+)(21.50±2.25)%明显降低(P<0.05)。观察组治疗后TNF-α(7.1±2.0)ng/ml、IL-6(111.6±20.5)pg/L、CRP(4.4±2.0)mg/L明显低于治疗前(15.3±2.6)ng/ml、(179.3±25.8)pg/L、(9.8±2.8)mg/L及对照组治疗后(9.3±2.2)ng/ml、(138.6±21.2)pg/L、(6.7±2.3)mg/L(P<0.05)。观察组的不良反应发生率为51.43%(18/35),与对照组42.86%(15/35)比较,无显著性差异(χ^(2)=0.516,P=0.473>0.05)。结论窄谱中波紫外线联合阿维A治疗寻常型银屑病可提高临床疗效,调节T淋巴细胞功能失衡,降低炎症细胞因子,且安全性高,值得推广。

浅层X线联合维A酸类药物治疗顽固性跖疣一例并文献复习

跖疣是发生于足底的寻常疣,治疗方法包括破坏性疗法、抗增生疗法、免疫疗法等。我们报道一例弥漫性、顽固性跖疣患者,曾应用冷冻治疗、激光治疗、药物治疗等均无效,经浅层X线一次联合维A酸类药物治疗,2个月后皮疹基本痊愈。

卡泊三醇联合阿维A胶囊治疗寻常型银屑病的效果分析

目的:分析卡泊三醇联合阿维A胶囊治疗寻常型银屑病的效果。方法:选取2020年6月—2021年6月沂水县人民医院收治的寻常型银屑病患者124例作为研究对象,依据随机数字表法分为两组,各62例。对照组予以阿维A胶囊治疗,观察组在对照组基础上应用卡泊三醇软膏治疗。比较两组治疗效果、皮损情况及不良反应发生率。结果:治疗后,两组皮损严重程度评分低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.013)。观察组不良反应总发生率低于对照组,差异有统计学意义(P=0.027)。结论:卡泊三醇联合阿维A胶囊治疗寻常型银屑病的效果较好,可改善患者临床症状,不良反应发生率低。

丹青胶囊联合阿维A胶囊治疗寻常型银屑病血瘀证的临床研究

目的探讨丹青胶囊联合阿维A胶囊治疗寻常型银屑病血瘀证的临床研究。方法选择2022年1—6月本院门诊治疗的62例寻常型银屑病血瘀证患者作为研究对象,按照随机数表法分为对照组和治疗组两组,每组各31例。对照组采用阿维A胶囊治疗,20 mg/次,1次/d;治疗组在对照组治疗的基础上给予口服丹青胶囊,4粒/次,3次/d,两组共计治疗8周。比较两组治疗后临床疗效、PASI和DLQI评分、Th1、Th2、Th17和Treg细胞百分比及其分泌的细胞因子表达水平的差异。结果8周后,与对照组相比,治疗组总有效率明显升高(96.77%vs.77.42%,χ2=5.167,P=0.023)。治疗后,与对照组相比,治疗组PASI评分[(3.23±0.84)分vs.(7.23±1.02)分]、DLQI[(12.04±3.11)分vs.(15.75±2.97)分]、Th1细胞百分比[(3.74±0.26)%vs.(5.26±0.48)%]、Th1/Th2细胞比值[(1.16±0.13)vs.(1.77±0.10)]、Th17细胞百分比[(5.04±0.63)%vs.(8.17±1.02)%]、Th17/Treg细胞比值[(0.63±0.07)vs.(1.14±0.05)]、IFN-g[(8.74±2.21)pg/ml vs.(15.63±2.79)pg/ml]和IL-17[(11.59±1.53)pg/ml vs.(19.74±1.16)pg/ml]表达水平明显降低,差异均具有统计学意义(P<0.05),而Treg细胞百分比[(8.17±1.25)vs.(6.38±0.69)]、IL-4[(133.04±20.71)pg/ml vs.(102.67±17.52)pg/ml]和TGF-α[(40.55±4.36)pg/ml vs.(32.35±3.49)pg/ml]表达水平明显升高,差异均具有统计学意义(P<0.05)。对照组和治疗组不良反应发生率分别为16.13%和22.58%,组间差异无统计学意义(χ2=0.413,P=0.520)。结论丹青胶囊治疗寻常型银屑病血瘀证临床疗效显著,安全性高,可能与改善Th1/Th2和Th17/Treg细胞失衡有关。

银屑胶囊联合阿维A胶囊治疗寻常型银屑病患者的效果

目的:观察银屑胶囊联合阿维A胶囊治疗寻常型银屑病患者的效果。方法:选取2022年7月至2023年7月该院收治的200例寻常型银屑病患者进行前瞻性研究,按随机数字表法将其分为对照组(n=100)与观察组(n=100)。对照组采用阿维A胶囊治疗,观察组在对照组基础上联合银屑胶囊治疗,比较两组临床疗效,治疗前后皮肤瘙痒程度[四项目瘙痒量表(FIIQ)]评分、生命质量[皮肤病生活质量指数(DLQI)]评分、T细胞亚群指标[调节性T细胞(Treg)、辅助性T细胞1(Th1)、辅助性T细胞17(Th17)]水平、炎性因子[白细胞介素-6(IL-6)、白细胞介素-23(IL-23)、C反应蛋白(CRP)]水平,以及不良反应发生率。结果:观察组治疗总有效率为93.00%(93/100),高于对照组的82.00%(82/100),差异有统计学意义(P<0.05);治疗后,两组FIIQ、DLQI评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组Treg水平均高于治疗前,且观察组高于对照组,两组Th1、Th17水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组IL-6、IL-23、CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:银屑胶囊联合阿维A胶囊治疗寻常型银屑病患者可提高治疗总有效率,改善T细胞亚群指标水平,降低FIIQ评分、DLQI评分和炎性因子水平,其效果优于单纯阿维A胶囊治疗。

窄谱中波紫外线联合阿维A胶囊治疗斑块状银屑病疗效分析

目的分析窄谱中波紫外线联合阿维A胶囊治疗斑块状银屑病的临床疗效。方法选取2021年5月至2022年5月永城市人民医院收治的92例斑块状银屑病患者作为研究对象,按照不同治疗方法将其分为联合组(46例)和单一组(46例),联合组患者采用窄谱中波紫外线联合阿维A胶囊治疗,单一组患者单纯采用阿维A胶囊治疗,对比观察两组患者皮损情况、血清炎症因子水平、临床疗效及不良反应发生情况。结果治疗8周后,联合组患者银屑病皮损面积和严重程度指数(PASI)评分为(7.53±1.86)分、血清白细胞介素(IL)-17水平为(40.78±9.49)ng/ml、血清IL-22水平为(29.61±7.64)ng/ml,明显低于单一组患者的PASI评分(11.82±2.45)分、血清IL-17水平(54.23±11.62)ng/ml、血清IL-22水平(37.12±8.76)ng/ml(t=9.459、6.080、4.382,P均<0.001);治疗8周后,联合组患者治疗总有效率为91.30%,明显高于单一组患者的治疗总有效率71.74%(χ^(2)=5.845,P=0.016);治疗期间,联合组患者不良反应发生率为8.70%,与单一组患者的不良反应发生率15.22%无明显差异(χ^(2)=0.929,P=0.335)。结论与单纯应用阿维A胶囊相比,窄谱中波紫外线联合阿维A胶囊更有利于调节斑块状银屑病患者的血清IL-17、IL-22水平,减轻炎症细胞浸润程度,改善临床症状,且安全性较好。

阿维A对中、重度斑块状银屑病患者Th17细胞相关因子的影响

目的探讨阿维A治疗中、重度斑块状银屑病的疗效以及对银屑病患者血清Th17细胞相关因子IL-17,IL-22及IL-23的影响,进一步阐明阿维A治疗寻常性银屑病的作用机制。方法 35例中、重度斑块状银屑病患者口服阿维A治疗8周,以银屑病皮损面积和严重程度(PASI)评分评价疗效;采用ELISA法检测健康对照组以及银屑病治疗组使用阿维A治疗前后血清IL-17,IL-22及IL-23的水平。结果阿维A治疗前后PASI评分明显下降(P<0.01);银屑病组和健康对照组比较,IL-17,IL-22和IL-23的血清水平均明显增高(P<0.01);阿维A治疗后血清中IL-17的水平(45.38±11.69)pg/mL,IL-22的水平(61.48±18.76)pg/mL及IL-23的水平(139.65±40.28 pg/mL),较治疗前显著下降(P均<0.01)。结论银屑病患者的血清中存在高水平的IL-17,IL-22和IL-23;阿维A治疗中、重度银屑病疗效明显,治疗后血清中IL-17,IL-22和IL-23明显降低;阿维A可能通过影响Th17细胞相关因子来发挥治疗银屑病的作用。

阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病30例临床观察

目的评价阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病的临床疗效及安全性。方法将入选的91例红皮病型银屑病患者随机分为两组，全部患者予5％葡萄糖注射液加复方甘草酸苷60～80mL静滴，1次／d，新氢松软膏、薇诺娜柔润保湿霜外搽和温泉水疗；治疗组同时口服阿维A胶囊，起始剂量20—30mg，视病情变化，渐加量至每天60mg，渐减量至10～20mg维持治疗，治疗4周和8周时分别观察疗效。结果治疗4周时，治疗组有效率66．67％，对照组43．33％；治疗8周时，治疗组有效率为90．00％，对照组为61．67％，差异均有统计学意义（P〈0．05）。两组患者均无严重不良反应。结论阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病疗效好，能迅速控制病情，安全性高。

NB-UVB照射联合小剂量阿维A及外用他扎罗汀治疗重度斑块型银屑病疗效观察

入选的重度斑块型银屑病患者146例,采用随机方式,将病例分为治疗组(A组,n=49),给予窄谱中波紫外线(NB-UVB)照射,每周3次,并每晚外用0.05%他扎罗汀凝胶1次;单纯NB-UVB治疗组(B组,n=48),单纯给予NB-UVB照射;单纯他扎罗汀治疗组(C组,n=49),单纯给予0.05%他扎罗汀凝胶外用。3组患者均给予小剂量阿维A口服,4、8周后分别评价疗效,疗程结束12周随访复发情况。结果显示,A、B、C 3组有效率分别为93.9%、72.9%、69.4%,3组间比较差异有统计学意义(P<0.05),未出现较严重的毒副作用,A组复发率也明显低于B组和C组。

阿维A不同给药时间对寻常性银屑病疗效的影响

目的探讨阿维A治疗寻常性银屑病的最佳服药时间。方法选择90例寻常性银屑病患者随机分为早餐、中餐、晚餐3组。每组均以0.6mg/kg量予阿维A口服,同时予凡士林软膏外搽。共观察4周,分别于治疗前、治疗2周、治疗4周计算PASI评分并抽外周血检查TNF-α浓度,于治疗前后检查血常规及生化指标。同时记录不良反应。结果治疗后4周PASI评分比较,中餐组与早餐组和晚餐组比较差异均有统计学意义(P均<0.05)。治疗后4周TNF-α浓度比较,中餐组与早餐组和晚餐组比较差异均有统计学意义(P均<0.01)。不良反应方面,3组大部分病例均出现不同程度唇炎、口干、眼干、皮肤干燥脱屑等症状,均有肝酶及血脂升高。中餐组发生副作用的时间晚于其他组,且其他副作用的发生率低于另外两组。结论午餐服用阿维A治疗泛发性寻常性银屑病总体疗效优于早餐和晚餐,且不良反应发生率更低,发生时间更晚。

窄谱UVB联合阿维A酸治疗红皮病型银屑病

目的:观察311nm窄谱中波紫外线(NB-UVB)联合阿维A酸治疗红皮病型银屑病的疗效。方法:单独采用NB-UVB照射、单独应用阿维A酸治疗及NB-UVB联合阿维A酸治疗红皮病型银屑病95例,并以银屑病面积和严重度指数(PASI)评价疗效。结果:在(27.15±4.28)d、(28.52±5.31)d、(18.75±3.24)d治疗后,窄谱UVB照射组、阿维A酸治疗组、窄谱UVB联合阿维A酸治疗组治疗前后PASI评分改善率分别为(78.54±23.65)%、(79.16±22.89)%、(89.48±25.34)%;与阿维A酸治疗组比较,窄谱UVB照射组与其疗效相当(P>0.05),而窄谱UVB联合阿维A酸治疗组则在更短的治疗时间(P<0.05)取得了更好的疗效(P<0.05)。结论:窄谱UVB联合阿维A酸治疗红皮病型银屑病疗效好,不良反应少。我们于2004年1月至2004年10月单独应用窄谱中波紫外线(narrow-bandultravioletB,NB-UVB)照射、单独应用阿维A酸治疗及窄谱UVB联合阿维A酸治疗了95例红皮病型银屑病,现将观察和分析结果报告如下。1资料与方法1.1病例选择95例接受治疗的患者均为2004年1月至2004年10月在我科门诊及住院治疗的红皮病型银屑病患者,其中门诊患者60例,住院患者35例。仅采用NB-UVB照射治疗的30例患者,男16例,女14例,年龄(32.64±7.36)岁,病程(6.78±4.57)年;皮肤类型(根据Filzpalrick分类法,中国人的皮肤大多为Ⅲ型或Ⅳ型):Ⅲ型19例,Ⅳ型11例;仅应用阿维A酸口服治疗的30例患者,男15例,女15例,年龄(33.12±4.23)岁,病程(6.18±4.23)年;皮肤类型:Ⅲ型21例,Ⅳ型9例;采用NB-UVB联合阿维A酸治疗的35例患者,男17例,女18例,年龄(34.21±3.26)岁,病程(7.15±4.35)年;皮肤类型:Ⅲ型21例,Ⅳ型14例。3组患者的性别、年龄、病程、病型。